


Claims

1. A crystal of the compound of the following formula:




wherein the crystal has two or more peaks in diffraction angles (2θ) selected from $8.6\pm 0.2^\circ$, $14.1\pm 0.2^\circ$, $17.4\pm 0.2^\circ$, $20.0\pm 0.2^\circ$, $24.0\pm 0.2^\circ$, $26.3\pm 0.2^\circ$, $29.6\pm 0.2^\circ$ and $35.4\pm 0.2^\circ$ in an X-ray powder diffraction spectrum.

2. The crystal according to claim 1, wherein the crystal has peaks in diffraction angles (2θ) of: $8.6\pm 0.2^\circ$, $14.1\pm 0.2^\circ$, $17.4\pm 0.2^\circ$, $20.0\pm 0.2^\circ$, $24.0\pm 0.2^\circ$, $26.3\pm 0.2^\circ$, $29.6\pm 0.2^\circ$ and $35.4\pm 0.2^\circ$ in an X-ray powder diffraction spectrum.

3. A pharmaceutical composition comprising the crystal according to claim 1 and a pharmaceutically acceptable carrier or diluent.

4. A crystal of the compound of the following formula:




wherein the crystal has two or more peaks in diffraction angles (2θ) selected from $4.4\pm 0.2^\circ$, $8.9\pm 0.2^\circ$, $11.7\pm 0.2^\circ$, $14.9\pm 0.2^\circ$, $22.3\pm 0.2^\circ$, $24.4\pm 0.2^\circ$, $28.0\pm 0.2^\circ$ and $31.5\pm 0.2^\circ$ in an X-ray powder diffraction spectrum.

5. The crystal according to claim 4, wherein the crystal has peaks in diffraction angles (2θ) of $4.4\pm 0.2^\circ$, $8.9\pm 0.2^\circ$, $11.7\pm 0.2^\circ$, $14.9\pm 0.2^\circ$, $22.3\pm 0.2^\circ$, $24.4\pm 0.2^\circ$, $28.0\pm 0.2^\circ$ and $31.5\pm 0.2^\circ$ in an X-ray powder diffraction spectrum.

6. A pharmaceutical composition comprising the crystal according to claim 4 and a pharmaceutically acceptable carrier or diluent.

7. A crystal of the compound of the following formula:



wherein the crystal has two or more peaks in diffraction angles (2θ) selected from $4.4\pm 0.2^\circ$, $8.7\pm 0.2^\circ$, $10.6\pm 0.2^\circ$, $17.3\pm 0.2^\circ$, $17.5\pm 0.2^\circ$, $22.0\pm 0.2^\circ$, $24.0\pm 0.2^\circ$, $24.1\pm 0.2^\circ$ and $31.0\pm 0.2^\circ$ in an X-ray powder diffraction spectrum.

8. The crystal according to claim 7, wherein the crystal has peaks in diffraction angles (2θ) of $4.4\pm 0.2^\circ$, $8.7\pm 0.2^\circ$, $10.6\pm 0.2^\circ$, $17.3\pm 0.2^\circ$, $17.5\pm 0.2^\circ$, $22.0\pm 0.2^\circ$, $24.0\pm 0.2^\circ$, $24.1\pm 0.2^\circ$ and $31.0\pm 0.2^\circ$ in an X-ray powder diffraction spectrum.

9. A pharmaceutical composition comprising the crystal according to claim 7 and a pharmaceutically acceptable carrier or diluent.